Skip to content

Weight Loss as Treatment in Heart Disease

Intentional Weight Loss as Treatment in Obese Patients With Ischaemic Heart Disease

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02105805
Enrollment
30
Registered
2014-04-07
Start date
2010-10-31
Completion date
2011-08-31
Last updated
2014-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Keywords

intention weight loss, heart failure, 6-minute walk test

Brief summary

30 obese moderate-to-severe heart failure patients will be randomized to intervention or control in groups of 5-10 subjects. All will receive dietetic advice according to randomization and according to the European Heart Association. Intervention subjects will initiate with 8 weeks low energy diet, 800-1000 kcal/d by formula diet and subsequent four weeks reintroduction to regular foods supplying 1200 kcal/d substituting two daily meals with formula meal replacement. Control subjects are advised to follow the Nordic Nutrition Recommendations. Patients will be monitored by blood sampling and assessed by change in physical performance.

Interventions

BEHAVIORALDietetic group sessions

Group sessions to improve dietary adherence

Sponsors

University Hospital, Gentofte, Copenhagen
CollaboratorOTHER
University of Copenhagen
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* bmi \>30 * heart failure, moderate to severe, new york heart association II og III * stable disease * age \>18 years * out-patients * perform a six minutes walk test * given consent

Exclusion criteria

* unstable disease * insulin treated diabetes * pregnancy or lactating * unstable weight past 6 months (+- 10 kg) * planned procedures in the time of intervention

Design outcomes

Primary

MeasureTime frameDescription
Change in six minute walk test from baseline to week 16 (end of study)weeks 0 and 16Performance measure

Secondary

MeasureTime frameDescription
Change in lipid status from baseline to week 16 (end of study).weeks 0,1,2,4,6,8,10,12,14,16Blood sample and analyses for lipids

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026